Ultivue, a market leader in quantitative proteomic biomarker detection and advanced spatial tissue profiling, is unveiling its spatial insights platform, STARVUE™, at the American Association for Cancer Research (AACR) Annual Meeting. STARVUE™ is the culmination of Ultivue’s multi-year engineering efforts to bring the latest innovations in artificial intelligence and image data science to translational and clinical research applications, via a highly accurate and scalable analytical solution.
Through seamless analysis of data from InSituPlex® assays, known for their robust and highly specific biomarker detection, STARVUE™ empowers researchers with automated, high-confidence spatial insights into the tissue microenvironment. The resulting integrated analytical solution – a pairing of state-of-the-art chemistry and software – yields a workflow that saves months of time compared to manual, less quantitative methods.
The STARVUE™ platform harnesses the power of Ultivue’s flagship tissue-based image analysis applications: UltiStacker.AI™ and UltiAnalyzer.AI™. UltiStacker.AI™ utilizes state-of-the-art deep-learning models to co-register multiple rounds of multiplex immunofluorescence (mIF) and brightfield images of the same tissue specimen with micron-level accuracy. UltiAnalyzer.AI™ offers precise whole-slide mIF spatial image analysis using cutting-edge deep-learning algorithms for tissue detection, segmentation, cell segmentation, and cell-biomarker classification based on cell morphology and detected signal intensities. This new, AI-driven approach eliminates external subjective errors commonly associated with threshold-based image analysis methods and facilitates robust biomarker detection.
Ruben Cardenes, Director of AI Engineering at Ultivue, emphasized, “With UltiStacker.AI™ and UltiAnalyzer.AI™, we apply cutting-edge artificial intelligence to help researchers dive deeper into the intra- and inter-cellular dynamics of the tissue microenvironment, and gain accurate, actionable insights for their specific biological inquiries, faster.”
InSituPlex® assays offer an unparalleled dynamic range of biomarker detection through direct target detection and a proprietary isometric, single-molecule signal amplification that directly correlates detected signal intensity to the number of target molecules. The deep-learning models utilized in UltiAnalyzer.AI™ leverage accurately annotated training datasets from more than one petabyte of images of tissues stained with InSituPlex® assays, ensuring high precision in biomarker detection across various tissue indications and heterogeneous sample cohorts.
Also Read: Rachael Brake, PhD, Joins Zephyr AI as Chief Scientific Officer
Both software applications support highly scalable image analysis, capable of processing hundreds of images in parallel through Ultivue’s cloud-based infrastructure, which serves as the foundation of the STARVUE™ platform. Ultivue is also announcing an early-access program; through it, researchers can upload images acquired from running InSituPlex® assays in their own labs.
Moreover, the STARVUE™ platform seamlessly integrates powerful APIs and third-party web-based image visualization, annotation, and management applications within its cloud-based infrastructure. Users benefit from a seamless workflow for creating high-confidence, actionable insights from tissue samples, which enables effective evaluation of their biological hypotheses.
At AACR, Ultivue will present two posters showcasing UltiAnalyzer.AI™ cloud-based, high-throughput image analysis and management workflows, including integration of the OMERO Plus platform and AWS SageMaker with Ultivue software. Both posters are part of the Artificial Intelligence and Machine/Deep Learning 3 session: Poster Section 36, posters 28 and 29. Ultivue’s presentations at AACR also showcase capabilities related to OmniVUE™ configurable biomarker panels and 12-plex assay services, enabling the analysis of up to 12 biomarkers in a single assay.
“With the STARVUE™ image data science platform, we offer a comprehensive analytical solution that combines robust InSituPlex® assays with advanced AI-driven image analysis at scale,” said Rob Carson, President and Chief Executive Officer at Ultivue. “Through an integrated workflow, we help researchers obtain high-confidence spatial insights and derive actionable conclusions in precision oncology.”
SOURCE: PRNewswire